XNCR Xencor, Inc.

24.98
+0  (2%)
Previous Close 24.54
Open 24.80
Price To book 3.64
Market Cap 1.16B
Shares 46,573,000
Volume 291,369
Short Ratio 7.00
Av. Daily Volume 227,624

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial initiated March 2016. Initial data due 2018.
XmAb5871
Systemic Lupus Erythematosus (SLE)
Phase 2 top-line data due in 2017.
XmAb5871
IgG4-Related Disease (IgG4-RD)

Latest News

  1. Xencor to Present at 42nd Annual Deutsche Bank Health Care Conference
  2. Xencor, Inc. breached its 50 day moving average in a Bullish Manner : XNCR-US : April 25, 2017
  3. Xencor Appoints Kevin Gorman, Ph.D., to its Board of Directors
  4. Increased Earnings Estimates Seen for Xencor (XNCR): Can It Move Higher?
  5. Xencor, Inc. breached its 50 day moving average in a Bullish Manner : XNCR-US : March 27, 2017
  6. Novartis (NVS) Announces Positive Data on Heart Failure Drug
  7. Xencor to Present at Oppenheimer 27th Annual Healthcare Conference
  8. Xencor, Inc. breached its 50 day moving average in a Bearish Manner : XNCR-US : March 14, 2017
  9. Xencor Announces Bruce L.A. Carter, Ph.D., Chairman of the Board of Directors, Will Not Stand for Reelection to Board of Directors at 2017 Annual Meeting of Stockholders
  10. Xencor, Inc. :XNCR-US: Earnings Analysis: Q4, 2016 By the Numbers : March 3, 2017
  11. Xencor Presents Preclinical Data on Emerging Bispecific Antibody Candidates at American Association for Cancer Research (AACR) 2017 Annual Meeting
  12. Edited Transcript of XNCR earnings conference call or presentation 28-Feb-17 9:30pm GMT
  13. Xencor reports 4Q loss
  14. Xencor Reports Fourth Quarter and Full Year 2016 Financial Results
  15. Xencor to Host Fourth Quarter and Full Year 2016 Financial Results Webcast and Conference Call on February 28, 2017
  16. IgG4-Related Disease Biomarker Development Update Presented From an Ongoing, Open-label, Phase 2 Study of XmAb®5871 in IgG4-RD at the 3rd International Symposium on IgG4-Related Diseases & Fibrosis
  17. 3 Biotech Stocks to Buy in February
  18. Xencor to Present at Leerink Partners 6th Annual Global Healthcare Conference
  19. Xencor, Inc. – Value Analysis (NASDAQ:XNCR) : January 10, 2017
  20. Xencor, Inc. breached its 50 day moving average in a Bullish Manner : XNCR-US : January 9, 2017